naa a22 4500 510764088 CHVBK 20180411083150.0 cr unu---uuuuu 180411e20130801xx s 000 0 eng 10.1007/s12094-012-0987-8 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0987-8 Prognostic factors for acute toxicity in prostate cancer patients treated with high-dose hypofractionated radiotherapy [Elektronische Daten] [V. Macias, R. Gonzalez Celador, C. Marti-Macia, C. Cigarral, L. Perez-Romasanta] Purpose: To prospectively study acute genitourinary (GU) and gastrointestinal (GI) toxicity during hypofractionated radiotherapy. Patients and materials: One-hundred and seventy-one consecutive men with cT1-T3cN0cM0 prostate cancer were treated at 2.6Gy/fraction to a total dose of 67.6 for low risk (EQD2=79Gy) and 70.2Gy for intermediate-high risk (EQD2=82Gy) over 5.2-5.4weeks (α/β 1.5). Acute toxicity was scored according to RTOG/EORTC toxicity extended criteria after completing a 22-item questionnaire (basal, weekly, at 6months). Results: Minimum and median follow-up were 36 and 54.2months, respectively. GU toxicity grades 0, 1, 2 and 3 were found in 30.4, 37, 32 and 0.6% of patients, respectively. The figures for grades 0, 1, 2 and 3 GI toxicity were 66, 24, 10 and 0%. The highest degree of acute reactions was reached at 4-5weeks. At 6months, 15% of patients had GU toxicity (11% grade 1, 4% grade 2) and 5.8% GI toxicity (5.3% grade 1, 0.5% grade 2). Multivariate analysis shows that bladder volume receiving ≥65Gy (V 65) is associated with an increased risk of GU complications (p=0.017, HR=1.143, 95% CI=1.025-1.276), while history of TURP is linked to lower risk (p=0.002, HR=0.310, 95% CI 0.004-0.370). Mean rectal dose (p=0.013, HR=1.089, 95% CI 1.018-1.116) and total dose (p=0.019, HR=0.734, 95% CI 0.567-0.950) are significantly related to GI toxicity. Conclusions: This 5-week dose-escalation hypofractionated radiotherapy schedule that uses 3D-conformal radiotherapy without IGRT has resulted in <1% grade 3 acute complications. Our study suggests that reducing the mean rectal dose and the bladder V 65 helps prevent acute toxicity. TURP before radiotherapy was associated with lower acute GU toxicity. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Prostate cancer nationallicence Hypofractionated radiotherapy nationallicence Acute toxicity nationallicence Prognostic factors nationallicence Macias V. Servicio de Oncología Radioterápica, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, 37007, Salamanca, Spain aut Gonzalez Celador R. Public Health, University of Salamanca, Salamanca, Spain aut Marti-Macia C. Germans Trias I Pujol University Hospital, Badalona, Spain aut Cigarral C. Servicio de Oncología Radioterápica, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, 37007, Salamanca, Spain aut Perez-Romasanta L. Servicio de Oncología Radioterápica, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, 37007, Salamanca, Spain aut Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 643-651 1699-048X 15:8<643 2013 15 12094 https://doi.org/10.1007/s12094-012-0987-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0987-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Macias V. Servicio de Oncología Radioterápica, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, 37007, Salamanca, Spain aut NATIONALLICENCE 700 1- Gonzalez Celador R. Public Health, University of Salamanca, Salamanca, Spain aut NATIONALLICENCE 700 1- Marti-Macia C. Germans Trias I Pujol University Hospital, Badalona, Spain aut NATIONALLICENCE 700 1- Cigarral C. Servicio de Oncología Radioterápica, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, 37007, Salamanca, Spain aut NATIONALLICENCE 700 1- Perez-Romasanta L. Servicio de Oncología Radioterápica, Complejo Asistencial Universitario de Salamanca (CAUSA), Paseo de San Vicente 58-182, 37007, Salamanca, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/8(2013-08-01), 643-651 1699-048X 15:8<643 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer